7 Best Peptides for Fatigue

What to Know Before Choosing a Peptide for Fatigue

Fatigue is not a single problem. It shows up as post-exertional crashes in people with ME/CFS, as mental fog and flat affect after long stretches of stress, as sluggish mornings tied to poor sleep architecture, and as the kind of slow energy decline that builds over years of aging. Because the mechanisms behind each of those presentations differ, the peptides people reach for differ too. Some target mitochondrial function directly. Others work through the growth hormone axis and improve sleep quality as a downstream effect. A few address the immune and inflammatory load that sits underneath chronic fatigue in many people.

A compound earns a place on this list because people use it for fatigue, or are actively discussing using it. That is the whole test. FDA-approved compounds, telemedicine-prescribed peptides, and research-only compounds are all eligible, because what matters here is the honest field of options people encounter when they go looking. Evidence strength is stated plainly inside each entry rather than used as a filter. One compound on this list holds FDA approval for a narrow mitochondrial condition. Others have only preliminary human data. A few rest almost entirely on community-reported experience. That range is accurate, and it is more useful than a list that quietly filtered out anything with a thin evidence base.

The seven entries are numbered so the title has a spine, but the numbers reflect how prominently each compound appears in research and real-world use, not a claim that one is categorically better than another. Fatigue is individual enough that the ordering here is a starting point for understanding the field, not a prescription. The right match for your situation depends on the type of fatigue you are dealing with, your health history, and what else you are using.

1. SS-31 (Elamipretide): For Mitochondrial Energy Failure

SS-31, also known as elamipretide and approved under the brand name Forzinity for a rare mitochondrial heart condition called Barth syndrome, is a synthetic tetrapeptide that works at the mitochondrial inner membrane. Its mechanism is specific: it targets and stabilizes cardiolipin, a lipid molecule essential for the electron transport chain to function efficiently. When cardiolipin is unstable or depleted, the machinery that produces ATP, the cell's primary energy currency, runs poorly. SS-31 restores that structural integrity, and the downstream result is improved ATP synthesis and better mitochondrial output.

It is worth being precise about what that FDA approval does and does not mean. Forzinity is approved exclusively for Barth syndrome, a rare inherited disorder. It is not approved for general fatigue, age-related energy decline, ME/CFS, or any of the contexts in which people currently use it off-label. The approval came after Phase II and Phase III trials that make SS-31 the most clinically studied compound on this list for mitochondrial function, but those trials were in a specific rare-disease population. Off-label use for fatigue sits in investigational territory, and access outside the approved indication varies considerably.

Community reporting on SS-31 for fatigue is extensive and genuinely mixed. On the positive side, users describe it as eliminating fatigue in cases of CFS and long COVID, calling it the most effective approach they found for sustained energy. Several report enhanced cognitive clarity as a secondary effect. The effect people describe is not a stimulant boost: it reads more like a floor rising under the energy baseline, reduced crash rather than an acute hit of alertness. On the negative side, some users experienced paradoxical fatigue, where energy waned in the hours after administration. That pattern was often resolved by adding methyl-supporting supplements. Some users reported no benefit at all. The individual variability here is real and worth stating plainly.

For people whose fatigue has a clear mitochondrial or metabolic component, SS-31 is the compound with the deepest formal evidence base in this category. For general or lifestyle fatigue, the off-label picture is built on user experience rather than controlled trials.

2. MOTS-c: For Cellular Energy and Metabolic Efficiency

MOTS-c is a peptide encoded not in the nuclear genome but in mitochondrial DNA, specifically in the 12S ribosomal RNA gene. That origin makes it unusual. It functions as a signaling molecule that activates AMPK, the enzyme often described as the cell's energy sensor, and AMPK activation triggers a cascade that upregulates PGC-1alpha, the master regulator of mitochondrial biogenesis. Think of PGC-1alpha as the switch that tells cells to build more mitochondria and run the existing ones more efficiently. More mitochondria, working at higher capacity, means better ability to produce energy from glucose and fat. MOTS-c also works through what researchers call the Folate-AICAR-AMPK pathway, influencing how cells regulate their metabolic state under stress or high demand.

The human evidence for MOTS-c and fatigue is early-stage. No large randomized controlled trials measuring fatigue outcomes in humans have been published. What exists is strong mechanistic evidence from laboratory work and animal studies, alongside a growing body of user-reported experience that places MOTS-c among the compounds people most consistently reach for when the complaint is physical exhaustion or post-exertional energy failure. Community discussion repeatedly describes it as providing improved endurance and a reduction in the crash that follows exertion, rather than an acute energy lift. One user put it plainly: "Pricey, but definitely works" for tiredness.

MOTS-c is classified as an FDA Category 2 compound, which means it cannot be legally compounded in the United States under current regulations. People who use it do so through research or international sources. That access question is worth understanding before this compound makes anyone's shortlist.

For fatigue tied to cellular energy failure, especially age-related metabolic decline or post-exertional crashes, MOTS-c is the compound people most consistently discuss alongside SS-31. The two are often combined as a mitochondrial stack, targeting complementary aspects of the same underlying pathway.

3. CJC-1295 and Ipamorelin: For Sleep-Driven and Recovery Fatigue

CJC-1295 and Ipamorelin are almost always used together, and that pairing has become the most widely used peptide stack in the fatigue and recovery space. CJC-1295 is a synthetic analog of growth hormone releasing hormone and works by stimulating GHRH receptors in the pituitary. Ipamorelin is a growth hormone releasing peptide that acts on ghrelin receptors. When combined, they drive a reliable, pulse-like increase in growth hormone secretion that mirrors the natural rhythms the pituitary produces, rather than flooding the system with exogenous GH.

The link to fatigue is indirect but well-grounded. Growth hormone drives tissue repair, improves body composition, and improves sleep architecture, including the depth and quality of slow-wave sleep. For people whose fatigue is rooted in poor recovery, disrupted sleep, or the slow hormonal decline that comes with aging, restoring that GH pulse addresses a root contributor rather than masking a symptom.

No published randomized controlled trials demonstrate a direct reduction in fatigue scores in healthy adults using this stack. The evidence is mechanistic alongside user-reported: community discussion consistently describes the combination as providing a solid foundation for energy, sleep quality, and recovery over weeks to months of use. The effect is described as having a "foundation" quality that differs from the more acute mitochondrial effects some users report with SS-31 or MOTS-c. Reddit threads dedicated to whether fatigue improves with this combination show a generally positive pattern of responses, though individual results vary.

CJC-1295 and Ipamorelin are not FDA-approved for any indication. Their compounding status has been under FDA review, and access varies. They are among the most widely discussed peptides through telemedicine channels for age-related hormone decline and recovery support.

4. BPC-157: For Gut-Related and Inflammatory Fatigue

BPC-157 is a synthetic pentadecapeptide, fifteen amino acids long, derived from a partial sequence of a protein found in gastric juice. Its primary studied mechanisms are anti-inflammatory, angiogenic, and gut-protective: it promotes the growth of new blood vessels to damaged tissue, modulates the gut-brain axis, and suppresses inflammatory signaling. The fatigue connection runs through the gut and the immune system. Chronic gut dysfunction and persistent low-grade inflammation are increasingly recognized as contributors to systemic fatigue, and BPC-157's primary studied territory sits squarely in those pathways.

The evidence base for BPC-157 is almost entirely preclinical. No published randomized controlled trials in humans exist for fatigue or for most of its commonly discussed uses. What exists is extensive animal model data showing anti-inflammatory and tissue-repair effects, alongside a substantial volume of anecdotal reporting. Anyone evaluating this compound for fatigue is working from animal research and community experience, not clinical trial data.

Community experience with BPC-157 and fatigue splits noticeably. Some users describe dramatic improvement, particularly when gut symptoms or inflammation are part of the picture: better energy, reduced pain, improved sleep as secondary effects of gut repair. Others report that BPC-157 itself causes drowsiness, and the consistent community workaround is to take it in the evening rather than the morning. A subset of users with ME/CFS report that benefits did not persist beyond the protocol. BPC-157 was placed in the FDA Category 2 classification in 2023, restricting commercial compounding in the US, so access has become more limited than it was previously.

For people whose fatigue has a clear gut or inflammatory component, BPC-157 shows up regularly in community protocols as an option worth considering. For purely mitochondrial or hormonal fatigue, it occupies a more peripheral role in the discussion.

5. Thymosin Alpha-1: For Immune-Driven Fatigue

Thymosin Alpha-1 is a 28-amino acid peptide produced naturally by the thymus gland. Its primary studied function is immune modulation: it supports thymus function, enhances T-cell activity, and helps regulate the immune response. It is approved in more than 35 countries as a therapy for hepatitis and has been studied in contexts ranging from infection to cancer immunotherapy. The fatigue connection is mechanistic and observational: when fatigue is driven by immune dysregulation, chronic infection, or the immune exhaustion that follows prolonged illness, addressing the immune substrate is the logical target.

No dedicated randomized controlled trial has measured fatigue as a primary endpoint for Thymosin Alpha-1. The evidence for its use in this area is observational and mechanistic, built on the inference that immune modulation should reduce immune-driven energy drain, plus user-reported experience from people managing conditions like ME/CFS and chronic infection. One user cycling it alternately with Thymosin Beta-4 described feeling "much, much, much better," while another reported no noticeable effect, attributing the lack of response to a dose or duration that fell short of what was needed.

Thymosin Alpha-1 was placed in the FDA Category 2 classification in the US in 2024, meaning it cannot currently be compounded domestically. It remains accessible internationally through countries where it holds regulatory approval. For people whose fatigue traces clearly to immune dysfunction or chronic infection, Thymosin Alpha-1 is one of the more frequently discussed compounds in this space, and it carries a more established safety record than most others in this category given its long international approval history.

6. Semax: For Cognitive and Mental Fatigue

Semax is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone. Developed in Russia, where it has been used clinically for decades, it targets a different part of the fatigue landscape than the mitochondrial compounds above. Its primary effects are neurological: it enhances the expression of brain-derived neurotrophic factor, or BDNF, a protein that supports the growth and maintenance of neurons, and it activates PGC-1alpha in brain tissue, driving mitochondrial biogenesis specifically where cognitive demand is highest. The result is improved mental endurance, better focus under cognitive load, and a reduction in the fogginess and flat mental energy that characterize stress-related or cognitive fatigue.

Semax is not FDA-approved in the United States. Its evidence base for fatigue is largely community-reported in the Western literature, with some published work on neuroprotection and cognitive function from Russian and Eastern European research settings. No randomized controlled trials for fatigue specifically have been published in peer-reviewed Western journals. Users consistently describe it as providing improved cognitive clarity and stamina rather than a physical energy boost. One user described it as giving a "good boost for energy" alongside improved cognition. A smaller number of users reported a meaningful worsening of their condition, which illustrates the individual variability that runs through this entire field.

For mental fatigue, whether the complaint is brain fog, diminished focus under stress, or cognitive exhaustion after demanding work, Semax is one of the compounds people most consistently reach for. For physical or mitochondrial fatigue, it functions more as a secondary option, usually combined with compounds that address energy metabolism more directly.

7. NAD+ Precursors and 5-Amino-1MQ: For Cellular Energy Restoration

NAD+ sits at the center of cellular energy metabolism. As a coenzyme in cellular respiration, it is required for the reactions that produce ATP from glucose and fat. NAD+ levels decline meaningfully with age, and that decline is associated with reduced mitochondrial efficiency, slower repair processes, and the kind of low-grade fatigue that accumulates over years rather than appearing suddenly. The compounds in this category work by replenishing or protecting the NAD+ pool, rather than directly stimulating energy production.

The most widely available options are NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide), both oral supplements that serve as NAD+ precursors and are not peptides in the strict biochemical sense. They appear consistently alongside injectable peptide protocols in community stacks for fatigue. Published research confirms that NR and NMN effectively raise NAD+ levels in humans, though the evidence specifically connecting that increase to measurable fatigue reduction in clinical trials is less definitive than the mechanistic case would suggest.

5-Amino-1MQ works differently: it inhibits an enzyme called NNMT (nicotinamide N-methyltransferase), which is responsible for degrading NAD+, thereby protecting the existing NAD+ pool from breakdown rather than adding precursors to it. It requires access through compounding or research channels rather than being available as an over-the-counter supplement. The human clinical evidence for 5-Amino-1MQ specifically is thin. The evidence here is experiential rather than clinical, drawn from practitioner use and community reporting rather than published trials.

Community reports on NAD+ approaches for fatigue are consistently positive in aggregate. Users dealing with CFS and long COVID describe NAD+ as "very effective" and report that it meaningfully reduced their fatigue, though in stacked protocols it is sometimes difficult to isolate the benefit to any single component. NAD+ precursors are often used alongside mitochondrial peptides like SS-31 and MOTS-c as a cofactor strategy, addressing the cellular energy currency while the peptides target mitochondrial structure and signaling.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for fatigue?

No FDA-approved peptide exists specifically for treating fatigue, including ME/CFS or long COVID. SS-31 (elamipretide) holds FDA approval under the brand name Forzinity, but exclusively for Barth syndrome, a rare inherited mitochondrial heart condition. All other use of SS-31 for fatigue, and all use of every other compound on this list for that purpose, is off-label or investigational. That does not mean these compounds are unused or unserious, but it does mean anyone pursuing them is working outside formally approved indications.

How is mitochondrial fatigue different from regular tiredness?

Regular tiredness typically resolves with rest, sleep, or a reduction in the demands causing it. Mitochondrial fatigue tends to persist despite adequate sleep, worsen disproportionately after physical or mental effort, and resist the usual fixes. It reflects a problem at the cellular level, where the machinery that produces ATP is not keeping pace with demand. The compounds that target this most directly, SS-31 and MOTS-c in particular, aim to restore cellular energy production capacity rather than mask symptoms. The effect users describe is a rising floor under the energy baseline, a reduction in crash, not a stimulant response.

Can peptides for fatigue cause fatigue as a side effect?

Yes, and this is worth knowing before starting. Fatigue is one of the more commonly reported side effects during the initial phase of peptide therapy across multiple compound types. It tends to appear in the first few weeks and likely reflects the body adapting to changes in glucose homeostasis and metabolic signaling. SS-31 has a specific pattern worth noting: some users experience paradoxical fatigue in the hours after administration, which has been addressed in community protocols by adding methyl-supporting supplements. BPC-157 is known to cause drowsiness in some users, typically managed by shifting the dose to the evening.

Do these compounds work for chronic fatigue syndrome specifically?

None of the compounds on this list have been validated in randomized controlled trials specifically for ME/CFS. SS-31, MOTS-c, and NAD+ precursors appear most frequently in community reporting from people with CFS and long COVID, with some users describing meaningful improvement and others reporting little to no benefit. A proprietary investigational peptide called CT38 has been tested in an ME/CFS-specific clinical trial published in a peer-reviewed journal, with results showing safety and a meaningful reduction in symptoms, but it is not broadly accessible. The community consensus on peptides and CFS is cautious: they may support systems being addressed through other means, but they are not reliably curative, and individual variability is high.

Which of these is the most accessible starting point?

NAD+ precursors, specifically NR and NMN, are the most accessible entry point because they are available as oral supplements without a prescription. CJC-1295 and Ipamorelin are among the most widely available through telemedicine channels for people working with a prescribing clinician. The mitochondrial peptides, SS-31 and MOTS-c, are harder to obtain: SS-31's off-label availability is limited and MOTS-c's FDA Category 2 classification restricts domestic compounding. Semax and BPC-157 occupy a similar research-chemical tier in the United States. Practical access should factor into any evaluation alongside mechanism and evidence.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for fatigue in one place.